drug
PIRFENIDONE
Marketedupdated 3mo agoby Aizant Drug Research Solutions Pvt Ltd
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3indications
investigational
Pulmonary Fibrosis
all catalysts(1)
Trials studying PIRFENIDONE
- phase2A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood
- phase3Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)
- phase1A Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants
- phase1Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects
- phase3Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune Pneumonia
- phase2Phase ll Study of HEC585 in Patients With IPF
- phase3Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF
- —Real-life-persistence to Antifibrotic Treatments
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 22, 2026
32 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (67)
- Mar 28, 2037formulationUS 10188637
- Mar 28, 2037formulationUS 10188637
- Mar 28, 2037formulationUS 10188637
- Aug 30, 2033method-of-use (U-2045)US 8778947
- Aug 30, 2033method-of-use (U-1613)US 8778947
- Aug 30, 2033method-of-use (U-2045)US 8778947
- Aug 30, 2033method-of-use (U-2045)US 8778947
- Jan 8, 2030method-of-use (U-1603)US 78163833.4y
- Jan 8, 2030method-of-use (U-2042)US 78163833.4y
- Jan 8, 2030method-of-use (U-2042)US 78163833.4y
- Jan 8, 2030method-of-use (U-2050)US 78163833.4y
- Jan 8, 2030method-of-use (U-2049)US 79106103.4y
- Jan 8, 2030method-of-use (U-2048)US 79106103.4y
- Jan 8, 2030method-of-use (U-2049)US 79106103.4y
- Jan 8, 2030method-of-use (U-1604)US 79106103.4y
- Jan 8, 2030method-of-use (U-2082)US 80130023.4y
- Jan 8, 2030method-of-use (U-1603)US 80130023.4y
- Jan 8, 2030method-of-use (U-2082)US 80130023.4y
- Jan 8, 2030method-of-use (U-2047)US 80130023.4y
- Jan 8, 2030method-of-use (U-2054)US 80844753.4y
- Jan 8, 2030method-of-use (U-2054)US 80844753.4y
- Jan 8, 2030method-of-use (U-2054)US 80844753.4y
- Jan 8, 2030method-of-use (U-1605)US 80844753.4y
- Jan 8, 2030method-of-use (U-2081)US 83187803.4y
- Jan 8, 2030method-of-use (U-2081)US 83187803.4y
- Jan 8, 2030method-of-use (U-2046)US 83187803.4y
- Jan 8, 2030method-of-use (U-1606)US 83187803.4y
- Jan 8, 2030method-of-use (U-1611)US 86480983.4y
- Jan 8, 2030method-of-use (U-2052)US 86480983.4y
- Jan 8, 2030method-of-use (U-2051)US 86480983.4y
- Jan 8, 2030method-of-use (U-2051)US 86480983.4y
- Jan 8, 2030method-of-use (U-1612)US 87541093.4y
- Jan 8, 2030method-of-use (U-2053)US 87541093.4y
- Jan 8, 2030method-of-use (U-2053)US 87541093.4y
- Jan 8, 2030method-of-use (U-2053)US 87541093.4y
- Apr 22, 2029method-of-use (U-1600)US 75667292.7y
- Apr 22, 2029method-of-use (U-2270)US 75667292.7y
- Apr 22, 2029method-of-use (U-2077)US 75667292.7y
- Apr 22, 2029method-of-use (U-2077)US 75667292.7y
- Apr 22, 2029method-of-use (U-2073)US 76357072.7y
- Apr 22, 2029method-of-use (U-2074)US 76357072.7y
- Apr 22, 2029method-of-use (U-2076)US 76357072.7y
- Apr 22, 2029method-of-use (U-1609)US 76357072.7y
- Apr 22, 2029method-of-use (U-2060)US 85924622.7y
- Apr 22, 2029method-of-use (U-2062)US 85924622.7y
- Apr 22, 2029method-of-use (U-2059)US 85924622.7y
- Apr 22, 2029method-of-use (U-1609)US 85924622.7y
- Apr 22, 2029method-of-use (U-2066)US 86097012.7y
- Apr 22, 2029method-of-use (U-2070)US 86097012.7y
- Apr 22, 2029method-of-use (U-1610)US 86097012.7y
- Apr 22, 2029method-of-use (U-2064)US 86097012.7y
- May 10, 2028formulationUS 83831501.7y
- May 10, 2028formulationUS 83831501.7y
- May 10, 2028formulationUS 83831501.7y
- May 10, 2028formulationUS 83831501.7y
- Dec 18, 2027method-of-use (U-1601)US 76962361.3y
- Dec 18, 2027method-of-use (U-2080)US 77677001.3y
- Dec 18, 2027method-of-use (U-2080)US 77677001.3y
- Dec 18, 2027method-of-use (U-2080)US 77677001.3y
- Dec 18, 2027method-of-use (U-1601)US 77677001.3y
- Dec 18, 2027method-of-use (U-2079)US 84206741.3y
- Dec 18, 2027formulationUS 84206741.3y
- Dec 18, 2027method-of-use (U-2079)US 84206741.3y
- Dec 18, 2027method-of-use (U-2079)US 84206741.3y
- Sep 22, 2026formulationUS 776722532d
- Sep 22, 2026formulationUS 798899432d
- Sep 22, 2026formulationUS 875367932d
News(3)
- Behind the bell: Gearing up to go publicAvalyn Pharma and Generate Biomedicines executives discuss the long hours, hard work and rewarding moments of taking their companies public.biospace · 7d ago
- A PureTech startup banks $180M for a new IPF drugCelea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's Esbriet.biopharma_dive · 1mo ago
- Fierce Biotech Fundraising Tracker '26: Abcuro secures $66M; InduPro assembles $77MThe Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.fiercebiotech · 8mo ago
Data sources
last refreshed 34m ago
Found something off?
comments(0)
5-min edit window · permanent after that